ストックスクリーナーアプリを入手
14.39
1.77%
-0.26
Corvus Pharmaceuticals Inc (CRVS) 最新ニュース
Blue Owl Capital Holdings LP Takes Position in Corvus Pharmaceuticals, Inc. $CRVS - MarketBeat
Will Corvus’ Sharply Wider 2026 Losses Recast Its Risk‑Reward Profile for Investors (CRVS)? - simplywall.st
637,500 Shares in Corvus Pharmaceuticals, Inc. $CRVS Bought by DCF Advisers LLC - MarketBeat
Corvus (CRVS) Q2 2026 Results: The EPS Result Is Below Expectation; Market Response: The Stock Records a 3.84% Increase in the Current UpdateFinancial Health Score - Vinanet
Corvus Pharmaceuticals (CRVS): This Clinical-Stage Drugmaker Just Got A Lot More Interesting - Yahoo Finance
Corvus Pharmaceuticals (CRVS) Reports A Wider Loss, Is The Stock Still Cheap? - Sahm
CRVS Stock Surges 10%, Hits 50-DMA For First Time In A Month – Here’s Why Goldman Sachs Sees A 166% Upside - Stocktwits
Corvus Pharmaceuticals Stock Price Forecast. Should You Buy CRVS? - StockInvest.us
Renaissance Technologies LLC Takes $1.19 Million Position in Corvus Pharmaceuticals, Inc. $CRVS - MarketBeat
Analysts Offer Insights on Healthcare Companies: Atossa Therapeutics (ATOS), Corvus Pharmaceuticals (CRVS) and Perspective Therapeutics (CATX) - The Globe and Mail
Corvus: Evaluating Soquelitinib's Science, Market Reach, And Fair Value (NASDAQ:CRVS) - Seeking Alpha
HC Wainwright Issues Negative Estimate for CRVS Earnings - MarketBeat
Mizuho Securities Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $30 - Moomoo
HC Wainwright Brokers Decrease Earnings Estimates for CRVS - MarketBeat
The Manufacturers Life Insurance Company Buys 84,282 Shares of Corvus Pharmaceuticals, Inc. $CRVS - MarketBeat
H.C. Wainwright Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $27 - Moomoo
Corvus: Strong Buy Soquelitinib Q1 2027 Interim Futility Analysis And AD Drug Advancement - Seeking Alpha
Is Corvus Pharmaceuticals (CRVS) Undervalued After A Wider Q2 Loss? - Sahm
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Corvus Pharmaceuticals (CRVS) Gets a Buy from Oppenheimer - The Globe and Mail
Corvus Pharmaceuticals (NASDAQ:CRVS) Posts Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat
Corvus Pharmaceuticals Loss Widens to $18 Million as Soquelitinib Trial Costs Soar - finance.biggo.com
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap Down After Earnings Miss - MarketBeat
State Street Corporation (NYSE: STT) discloses 5.3% ownership in Corvus Pharmaceuticals - Stock Titan
Corvus Pharmaceuticals Inc (CRVS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CRVS SWOT Analysis: Financial Losses and Growth Potential Revealed in 10-Q Filing - GuruFocus
Corvus Pharmaceuticals Inc (CRVS) (Q2 2026) Earnings Call Highlights: Advancing Soquelitinib ... - Yahoo Finance
Corvus Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Corvus Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
Earnings call transcript: Corvus posts wider Q2 2026 loss as trials advance - Investing.com
Corvus Eczema Trial Is Expected to Enroll About 200 Patients - stocktitan.net
Corvus Pharmaceuticals, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Corvus Pharmaceuticals 2Q 2026: Net income $(17.96)M, EPS $(0.19) — 10-Q Summary - TradingView
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results - Yahoo Finance
Corvus Pharmaceuticals earnings up next as trial progress eyed By Investing.com - Investing.com Nigeria
8-K: Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Resultsmoomoo - Moomoo
82,890 Shares in Corvus Pharmaceuticals, Inc. $CRVS Acquired by Seven Fleet Capital Management LP - MarketBeat
Avidity Partners Management LP Invests $1.68 Million in Corvus Pharmaceuticals, Inc. $CRVS - MarketBeat
Vivo Capital LLC Has $41.05 Million Position in Corvus Pharmaceuticals, Inc. $CRVS - MarketBeat
Corvus Pharmaceuticals' Q2 Business Update Will Stream Live Aug. 6 - Stock Titan
Corvus Pharmaceuticals Inc (CRVS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - tradingkey.com
Corvus Pharmaceuticals Inc (CRVS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
BlackRock (CRVS holder) reports 7.5% beneficial stake in Corvus Pharmaceuticals - Stock Titan
Corvus Pharmaceuticals Inc (CRVS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CRVS|Corvus Pharmaceuticals Inc|Price:12.925|Chg%:-0.145 - TradingKey
Corvus Pharmaceuticals Inc (CRVS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Corvus Pharmaceuticals Inc (CRVS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Corvus Pharmaceuticals Inc (CRVS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Corvus Pharmaceuticals Inc (CRVS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Corvus Pharmaceuticals Inc (CRVS) Institutional Confidence - TradingKey
CRVS|Corvus Pharmaceuticals Inc|Price:13.070|Chg%:-0.610 - TradingKey
CRVS|Corvus Pharmaceuticals Inc|Price:13.950|Chg%:+0.580 - TradingKey
TradingKey - TradingKey
Corvus Pharmaceuticals, Inc. Revenue Breakdown – BX:C17 - tradingview.com
Corvus Pharmaceuticals director Ian T. Clark resigns from board - Bitget
Corvus Pharmaceuticals Announces Board Leadership Transition - TipRanks
Corvus Pharmaceuticals (CRVS) Slips 2.9% as Stock Tests Support Near $13.35Negative Gamma - dars.gov.et
Corvus Pharmaceuticals (CRVS) Q1 2026 earnings summary - Quartr
Corvus Pharmaceuticals (CRVS) Proxy filing Summary - Quartr
CRVS News | CORVUS PHARMACEUTICALS INC (NASDAQ:CRVS) - ChartMill
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):